Interpace Biosciences (IDXG) Q4 2024 earnings summary

Executive summary

• Net revenue increased 17% year-over-year to $46.9 million for 2024, driven by higher test volumes.

• Operating income from continuing operations rose to $8.1 million, up from $4.0 million in 2023.

• Net income for 2024 was $6.7 million, compared to $2.0 million in 2023.

• The company restated prior period financials due to improper royalty accruals, impacting 2016–2023 statements.

• A restructuring plan was approved in response to the loss of Medicare coverage for PancraGEN®, with implementation delayed pending CMS review.

Financial highlights

• Gross profit increased 19% to $29.9 million, with gross margin at 63.8% for 2024.

• Adjusted EBITDA was $8.7 million in 2024, up from $5.6 million in 2023.

• Cash and cash equivalents at year-end were $1.5 million; current liabilities totaled $10.6 million.

• Operating cash flow was $4.6 million for 2024, up from $3.8 million in 2023.

• No dividends declared; all earnings retained for business operations.

Outlook and guidance

• PancraGEN® test coverage loss by CMS is expected to significantly impact revenue; restructuring aims to offset lost revenue with $12.5–$14.5 million in cost reductions.

• The company is focused on expanding its thyroid and lung cancer test franchises and developing new products.

• Strategic alternatives and new funding sources are being explored to support liquidity.